Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Crystal L Mackall"'
Autor:
Jasia Mahdi, Jorg Dietrich, Karin Straathof, Claire Roddie, Brian J. Scott, Tom Belle Davidson, Laura M. Prolo, Tracy T. Batchelor, Cynthia J. Campen, Kara L. Davis, Juliane Gust, Michael Lim, Robbie G. Majzner, Julie R. Park, Sonia Partap, Sneha Ramakrishna, Rebecca Richards, Liora Schultz, Nicholas A. Vitanza, Leo D. Wang, Crystal L. Mackall, Michelle Monje
Publikováno v:
Nature Medicine. 29:803-810
Autor:
Zinaida Good, Jay Y. Spiegel, Bita Sahaf, Meena B. Malipatlolla, Zach J. Ehlinger, Sreevidya Kurra, Moksha H. Desai, Warren D. Reynolds, Anita Wong Lin, Panayiotis Vandris, Fang Wu, Snehit Prabhu, Mark P. Hamilton, John S. Tamaresis, Paul J. Hanson, Shabnum Patel, Steven A. Feldman, Matthew J. Frank, John H. Baird, Lori Muffly, Gursharan K. Claire, Juliana Craig, Katherine A. Kong, Dhananjay Wagh, John Coller, Sean C. Bendall, Robert J. Tibshirani, Sylvia K. Plevritis, David B. Miklos, Crystal L. Mackall
Publikováno v:
Nature Medicine. 28:1860-1871
Autor:
Robbie G. Majzner, Crystal L. Mackall
Publikováno v:
Nature Medicine. 25:1341-1355
Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed expectations, driving an ever-expanding number of clinical trials and the first US Food and Drug Administration approvals of cell therapies for the treatment of canc
Autor:
Staci Martin, Robbie G. Majzner, Constance M. Yuan, Bonnie Yates, Jack F. Shern, Haneen Shalabi, Haiying Qin, David F. Stroncek, Marianna Sabatino, Terry J. Fry, Boro Dropulic, Cindy Delbrook, Yang Feng, Nirali N. Shah, Thomas J. Fountaine, Rimas J. Orentas, Daniel W. Lee, Crystal L. Mackall, Maryalice Stetler-Stevenson, Sneha Ramakrishna, Pamela L. Wolters, Dimiter S. Dimitrov, Ling Zhang, Sang M. Nguyen
Publikováno v:
Nature Medicine. 24:20-28
Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent effects in relapsed and/or refractory pre-B cell acute lymphoblastic leukemia (B-ALL), but antigen loss is a frequent cause of resistance to CD19-targeted immunotherapy. CD22 is al
Autor:
Jack F. Shern, Meera Murgai, Terry J. Fry, Alec J. Walker, M. Eric Kohler, Rimas J. Orentas, Crystal L. Mackall, Maria Ingaramo, Rosandra N. Kaplan, Kelsey Wanhainen, Adrienne H. Long, Waleed Haso, Jillian P. Smith, George H. Patterson, Vikas R Venkateshwara
Publikováno v:
Nature medicine
Chimeric antigen receptors (CARs) targeting CD19 have mediated dramatic antitumor responses in hematologic malignancies, but tumor regression has rarely occurred using CARs targeting other antigens. It remains unknown whether the impressive effects o
Autor:
Charles S. Carter, Hua Zhang, Margaret V. Brown, Brenna J. Hill, Daniel C. Douek, Thomas A. Fleisher, Lauren M. Long, Jay A. Berzofsky, Martin Guimond, Donna Bernstein, Elizabeth J. Read, Kevin S. Chua, Veena Kapoor, Crystal L. Mackall, Lee J. Helman
Publikováno v:
Nature Medicine. 11:1238-1243
CD4(+)CD25(+) regulatory T (T(reg)) cells have a crucial role in maintaining immune tolerance. Mice and humans born lacking T(reg) cells develop severe autoimmune disease, and depletion of T(reg) cells in lymphopenic mice induces autoimmunity. Interl